Study
|
FGF
|
Follow-up†, weeks
|
Patients FGF/PB
|
Male, % FGF/PB
|
Age†, y FGF/PB
|
BMI ‡, FGF/PB
|
Fibrosis stage III/IV, %
FGF/PB
|
ALT, U/liter FGF/PB
|
TG, mg/ml FGF/PB
|
HbA1c,%
FGF/PB
|
BALANCED 2021 |
Efruxifermin |
30 |
59/21 |
47.5/28.5 |
52.0/52.4 |
37.5/37.6 |
28.8/38 |
57.4/50.7 |
177.7/208.3 |
6.28/6.49 |
HARMONY 2023 |
Efruxifermin |
96 |
85/43 |
38.8/37.2 |
54.4/ 55 |
37.7/38.7 |
63.5/69.7 |
56.5/62.2 |
156.1/ 169.7 |
6.7/
6.8 |
ENLIVEN 2023 |
Pegozafermin |
46 |
151/71 |
36.4/32 |
55.2/56.3 |
35.8/38.1 |
64.9/69.1 |
58.7/49.6 |
172.6/170.3 |
6.6/6.6 |
FALCON 1 2024 |
Pegbelfermin |
48 |
148/49 |
41,2/40,8 |
56.6/57.5 |
35.6/35.2 |
100 |
53.4/53.4 |
163.8/ 200.4 |
6.8/6.9 |
FALCON 2 2024 |
Pegbelfermin |
121 |
115/39 |
35.6/38.4 |
58.6/61.4 |
35.6/35.4 |
100 |
48.7/48.3 |
154.0/133.4 |
6.9/7.0 |
Sanyal 2018 |
Pegbelfermin |
16 |
49/26 |
34.6/38.4 |
52/47 |
34.4/37 |
7/1 |
67.9/80 |
198.2/ 171 |
6.1/6.0 |
Loomba 2023 |
Pegozafermin |
53 |
62/19 |
38.7/36.8 |
51.7/52.6 |
34.8/33.8 |
NA |
42.2/38.8 |
NA |
NA |
BALANCED Cohort C 2023 |
Efruxifermin |
16 |
20/10 |
20/70 |
57.1/61.1 |
36.0/39.1 |
NA |
31.7/32.7 |
134.6/121.7 |
6.1/
6.6 |